Variant · Snv
ERBB2 R34Q
CI-VAR-00003833Explore in graph →CIViC 4599
Curated evidence
Evidence by cancer (1 items)
Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.
civicProvenance
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 29967253
- Run
- ING-CIVIC-20260908-000001
| Molecular profile | Therapy | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| Malignant Neoplasm1 | ||||||||
| ERBB2 R34Q | Afatinib + Lapatinib + Neratinib + Osimertinib + TrastuzumabSubstitutes | Predictive | D | Supports Sensitivity Response | 3 | submitted | EID11600The drug sensitivity of 55 non-synonymous ERBB2 missense variants were assessed using the mixed-all-nominated-in-one (MANO) method, both in vitro (introduced into Ba/F3 cells; experiment conducted in … (full text at CIViC) PMID 29967253 · Nagano et al., 2018 · Open in CIViC | civic |
ClinVar
Clinical significance (0)
ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.
Data not yet available
No ClinVar interpretation attached to this variant.